A second chance for telomerase reverse transcriptase in anticancer immunotherapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A second chance for telomerase reverse transcriptase in anticancer immunotherapy
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 14, Issue 2, Pages 115-128
Publisher
Springer Nature
Online
2016-06-01
DOI
10.1038/nrclinonc.2016.67
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- (2016) Scott Antonia et al. LANCET ONCOLOGY
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation
- (2015) Dong-Sheng Huang et al. EUROPEAN JOURNAL OF CANCER
- Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8+ T Lymphocytes
- (2015) Wong Yu et al. IMMUNITY
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
- (2015) Douglas Marvel et al. JOURNAL OF CLINICAL INVESTIGATION
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics
- (2015) Maurizio Zanetti JOURNAL OF IMMUNOLOGY
- Telomerase activation by genomic rearrangements in high-risk neuroblastoma
- (2015) Martin Peifer et al. NATURE
- Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy
- (2015) Shabnam Shalapour et al. NATURE
- Recurrent somatic mutations in regulatory regions of human cancer genomes
- (2015) Collin Melton et al. NATURE GENETICS
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
- (2015) Jeanette E. Eckel-Passow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- TERTpromoter mutations and telomerase reactivation in urothelial cancer
- (2015) Sumit Borah et al. SCIENCE
- The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
- (2015) R. J. A. Bell et al. SCIENCE
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Variation in cancer risk among tissues can be explained by the number of stem cell divisions
- (2015) C. Tomasetti et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma
- (2015) Mohamed Ali Mosrati et al. Oncotarget
- Cancer-associated TERT promoter mutations abrogate telomerase silencing
- (2015) Kunitoshi Chiba et al. eLife
- B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas
- (2014) Nesrine I. Affara et al. CANCER CELL
- Regulatory T cells in cancer immunotherapy
- (2014) Hiroyoshi Nishikawa et al. CURRENT OPINION IN IMMUNOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
- (2014) Gary Middleton et al. LANCET ONCOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genome-wide analysis of noncoding regulatory mutations in cancer
- (2014) Nils Weinhold et al. NATURE GENETICS
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma
- (2014) Barbara Heidenreich et al. Nature Communications
- Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells
- (2014) Giovanna Bossi et al. OncoImmunology
- Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
- (2013) Einar Osland Vik-Mo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer
- (2013) Daniela Fenoglio et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Highly prevalentTERTpromoter mutations in bladder cancer and glioblastoma
- (2013) Xiaoli Liu et al. CELL CYCLE
- Trouble upstream
- (2013) E. Elizabeth Patton et al. NATURE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
- (2013) Yared Hailemichael et al. NATURE MEDICINE
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Human Prostate Adenocarcinomas Harbor Androgen-Independent Cancer Cells
- (2013) Rita R. Fiñones et al. PLoS One
- TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism
- (2013) P. S. Rachakonda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
- (2013) P. J. Killela et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TERT Promoter Mutations in Familial and Sporadic Melanoma
- (2013) S. Horn et al. SCIENCE
- Highly Recurrent TERT Promoter Mutations in Human Melanoma
- (2013) F. W. Huang et al. SCIENCE
- Telomerase: central regulator of all of the hallmarks of cancer
- (2013) Kee Chung Low et al. TRENDS IN BIOCHEMICAL SCIENCES
- Frequency of TERT promoter mutations in human cancers
- (2013) João Vinagre et al. Nature Communications
- High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions
- (2013) Jean Charles Nault et al. Nature Communications
- Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity
- (2013) J. Yan et al. Cancer Immunology Research
- Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
- (2013) Robert Wesolowski et al. Journal for ImmunoTherapy of Cancer
- A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
- (2012) Tim F Greten et al. BMC CANCER
- Telomere-Driven Tetraploidization Occurs in Human Cells Undergoing Crisis and Promotes Transformation of Mouse Cells
- (2012) Teresa Davoli et al. CANCER CELL
- Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
- (2012) Eva Ellebaek et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Antitelomerase Therapy Provokes ALT and Mitochondrial Adaptive Mechanisms in Cancer
- (2012) Jian Hu et al. CELL
- Telomerase Reactivation following Telomere Dysfunction Yields Murine Prostate Tumors with Bone Metastases
- (2012) Zhihu Ding et al. CELL
- Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
- (2012) M. Dosset et al. CLINICAL CANCER RESEARCH
- Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response
- (2012) Y. Godet et al. CLINICAL CANCER RESEARCH
- Regulation of the human catalytic subunit of telomerase (hTERT)
- (2012) Michael Daniel et al. GENE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telomerase reverse transcriptase promotes epithelial–mesenchymal transition and stem cell-like traits in cancer cells
- (2012) Z Liu et al. ONCOGENE
- Cell-Extrinsic Effects of Tumor ER Stress Imprint Myeloid Dendritic Cells and Impair CD8+ T Cell Priming
- (2012) Navin R. Mahadevan et al. PLoS One
- Cancer stem cells and epithelial–mesenchymal transition: Concepts and molecular links
- (2012) Christina Scheel et al. SEMINARS IN CANCER BIOLOGY
- Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?
- (2012) Yann Godet et al. OncoImmunology
- Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes
- (2011) Christopher M. Heaphy et al. AMERICAN JOURNAL OF PATHOLOGY
- Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study
- (2011) A. Kotsakis et al. ANNALS OF ONCOLOGY
- Vaccination of patients with cutaneous melanoma with telomerase-specific peptides
- (2011) Robert E. Hunger et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients
- (2011) J. A. Kyte et al. CLINICAL CANCER RESEARCH
- Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
- (2011) P. F. Brunsvig et al. CLINICAL CANCER RESEARCH
- Cross-priming of CD8+ T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia
- (2011) Toshio Kitawaki et al. EXPERIMENTAL HEMATOLOGY
- Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes
- (2011) Jason Greenbaum et al. IMMUNOGENETICS
- Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma
- (2011) Christoph Schlapbach et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Tumor Stress Inside Out: Cell-Extrinsic Effects of the Unfolded Protein Response in Tumor Cells Modulate the Immunological Landscape of the Tumor Microenvironment
- (2011) N. R. Mahadevan et al. JOURNAL OF IMMUNOLOGY
- The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation
- (2011) E. Caron et al. Molecular Systems Biology
- A human memory T cell subset with stem cell–like properties
- (2011) Luca Gattinoni et al. NATURE MEDICINE
- Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference
- (2011) Tong Xu et al. PROSTATE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Role of telomeres and telomerase in cancer
- (2011) Jerry W. Shay et al. SEMINARS IN CANCER BIOLOGY
- Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo
- (2010) O. Adotevi et al. BLOOD
- Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma
- (2010) A. P. Rapoport et al. BLOOD
- Identification of CD133−/Telomeraselow Progenitor Cells in Glioblastoma-Derived Cancer Stem Cell Lines
- (2010) Fabian Beier et al. CELLULAR AND MOLECULAR NEUROBIOLOGY
- Naturally occurring tumor-specific CD8+ T-cell precursors in individuals with and without cancer
- (2010) Vaios Karanikas et al. IMMUNOLOGY AND CELL BIOLOGY
- Alternative lengthening of telomeres: models, mechanisms and implications
- (2010) Anthony J. Cesare et al. NATURE REVIEWS GENETICS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes
- (2009) S. Ugel et al. BLOOD
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing
- (2009) J. D. Freeman et al. GENOME RESEARCH
- Hepatitis C virus core protein enhances Telomerase activity in Huh7 cells
- (2009) Zhaowen Zhu et al. JOURNAL OF MEDICAL VIROLOGY
- A p53-Dependent Response Limits Epidermal Stem Cell Functionality and Organismal Size in Mice with Short Telomeres
- (2009) Ignacio Flores et al. PLoS One
- How Telomeres Solve the End-Protection Problem
- (2009) T. de Lange SCIENCE
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
- (2009) M. Olivier et al. Cold Spring Harbor Perspectives in Biology
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Characterization of primitive hematopoietic cells from patients with dyskeratosis congenita
- (2008) F. D. Goldman et al. BLOOD
- Presentation of Telomerase Reverse Transcriptase, a Self-Tumor Antigen, is Down-regulated by Histone Deacetylase Inhibition
- (2008) I. Pellicciotta et al. CANCER RESEARCH
- Preventive Vaccination with Telomerase Controls Tumor Growth in Genetically Engineered and Carcinogen-Induced Mouse Models of Cancer
- (2008) C. Mennuni et al. CANCER RESEARCH
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
- (2008) Sendurai A. Mani et al. CELL
- CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer
- (2008) Rong-Fu Wang HUMAN IMMUNOLOGY
- Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma
- (2008) Annika Berntsen et al. JOURNAL OF IMMUNOTHERAPY
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started